The efficacy, immunogenicity and safety of a recombinant tetrameric gE-Fc fusion protein vaccine for herpes zoster in adults 40 years of age or older：a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Related documents

• Automated hippocampal sclerosis detection, using AID-HS, shows robust performance across multi-centre paired 7T and 3T MRI#658776
• Evaluation of risk stratification at presentation using the Alinity high-sensitivity cardiac troponin I assay#658777
• A multimodal investigation of perceptual awareness in Alzheimer's disease#658778
• The timeline of brain aging in major depression: A prospective study from before first-onset to established illness#658779
• Mapping the Health Burden of Neighbourhood Deprivation: Neurobiological Evidence Across the Life Span#658780